drugset / Trial / NCT00045006
Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer
Treatment
Summary
RATIONALE: Suberoylanilide hydroxamic acid may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth. PURPOSE: Phase I trial to study the effectiveness of suberoylanilide hydroxamic acid in treating patients who have advanced cancer.
Timeline
- Start
- 2001-07
- Primary completion
- 2005-12
- Completion
- 2008-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Vorinostat | Small molecule | — | Intravenous |